STAT3 and non-small cell lung carcinoma: In addition, STAT3-inhibiting therapy could be limited due to accompanying adverse drug reactions, including infections, rectal hemorrhage, abnormal liver function, thrombocyto- and neutropenia, anemia, and neurological disorders.[41] Therefore, there is an urgent need to exploit new therapeutic targeting core components in development of NSCLC with potent efficacy and safety in the clinic.